Framingham Heart Study

Schaefer EJ, Bongard V, Beiser AS, Lamon-Fava S, Robins SJ, Au R, Tucker KL, Kyle DJ, Wilson PW, Wolf PA. (2006) Plasma phosphatidylcholine docosahexaenoic acid content and risk of dementia and Alzheimer disease The framingham heart study. Arch Neurol 63 1545-1550. [Pg.398]

Lauer MS, Anderson KM, Kannel WB, et al. The impact of obesity on left ventricular mass and geometry. The Framingham Heart Study. JAMA. Jul 10 1991 266(2) 231-236. [Pg.142]

O Donnell CJ, Larson MG, Feng D, etal. Framingham Heart Study, Genetic and environmental contributions to platelet aggregation the Framingham heart study. Circulation 2001 103 3051-3056. [Pg.152]

Surrogate endpoints are particularly useful in cases where the clinical endpoints occur after long periods. This is particularly relevant to cardiovascular disease. High blood pressure is a well-established cardiovascular surrogate endpoint it is well established that chronic high blood pressure is causative of cardiovascular and cerebrovascular events. Kannel and Sorlie (1975) commented on data from the Framingham Heart Study, a major prospective cardiovascular study of over 5,000 individuals ... [Pg.78]

Singh JP, Evans JC, Levy D, et al. Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study). Am J Cardiol 1999 83 897-902. [Pg.435]

Hubert, H.B. et al.. Obesity as an independent risk factor for cardiovascular disease a 26-year follow-up of participants in the Framingham Heart Study, Circulation, 61, 968, 1983. [Pg.139]

Eox CS, Coady S, Sorlie PD, D Agostino RB, Sr., Pencina MJ, Vasan RS, et al. Increasing cardiovascular disease burden due to diabetes mellitus The Framingham Heart Study. Circulation 2007 115 1544-1550. [Pg.1028]

A variety of biomarkers have been shown to be valuable individually for one or several toxicant or disease situations. Few of these biomarkers have been systematically evaluated for the plethora of situations that might provoke false positive responses. Acceleration of the current pace of biomarker evaluation and qualification demands (a) the availability of panels of biomarker-assays that can be comparatively evaluated on well-defined common sample sets, (b) fit-for-purpose performance evaluation in controlled animal studies with carefully benchmarked histological endpoints and samples from well-defined focused clinical trial cohorts, and (c) ready availability of banked blood and urine sample archives from clinical trial populations with carefully documented morbidities such as the Framingham Heart Study,45 or the Drug-Induced Liver Injury Network (DILIN) prospective study,46 to name a few. Availability of such panels of validated biomarker assays and well-documented preclinical and clinical samples, as well as increased cooperation between animal model researchers and clinical researchers will enable individual biomarkers to be qualified for sensitivity of specifically defined adverse events, qualified for appropriate specificity using samples of defined benign events, and collected into panels that yield complementary information about the health and safety of animals and patients. [Pg.310]

Plasma lipid and lipoprotein concentrations in male and female subjects are presented in Tables 26-7 through 26-10. These reference intervals have been developed using the Lipid Research CHnics (LRC) population. Although reference intervals for apo A-I and B-lOO from the Framingham Heart Study using the approved World Health Organiza-tion/Internationai Federation of Clinical Chemistry and Laboratory Medicine (IFCC) calibrators have been published,distributions of these two proteins that better reflect the North American population have only recently... [Pg.922]

McNamara JR, Shah PK, Nakajima K, Guppies LA, Wilson PWF, Ordovas JM, Schaefer EJ. Remnant lipoprotein cholesterol and triglyceride reference ranges fi om the Framingham Heart Study. Clin Chem 1998 44 1224-32. [Pg.975]

Vasan RS, Benjamin EJ, Larson MG, Leip EP, Wang TJ, Wilson PW, et al. Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction the Framingham heart study. JAMA 2002 288 1252-9. [Pg.1669]

Guidry UC, Evans JC, Larson MG, Wilson PW, Murabito JM, Levy D. Temporal trends in event rates after Q-wave myocardial infarction the Framingham Heart study. Circulation 1999 100 2054. [Pg.315]

Joehanes R, Johnson AD, Barb JJ et al (2012) Gene expression analysis of whole blood, peripheral blood mononuclear cells, and lym-phoblastoid cell lines from the Framingham Heart Study. Physiol Genomics 44 59-75... [Pg.42]

Sundstrom J, Evans JC, Benjamin EJ, Levy D, Larson MG, Sawyer DB, Siwik DA, Colucci WS, Sutherland P, Wilson PW, Vasan RS (2004) Relations of plasma matrix metalloproteinase-9 to clinical cardiovascular risk factors and echo-cardiographic left ventricular measures the Framingham Heart Study. Circulation 109(23 ) 2850-2856.doi 10.1161/01. CIR.0000129318. 79570.84... [Pg.477]

Wang TJ, Larson MG, Levy D, et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality The Framingham Heart Study. Circulation 2003 107 2920—2925. [Pg.258]

Sytkowski PA, D Agostino RB, Belanger A, Kannel WB. Sex and time trends in cardiovascular disease incidence and mortality The Framingham Heart Study, 1950-1989. Am J Epidemiol 1996 143 338-350. [Pg.287]

Culleton BF, Larson MG, Evans JC, et al. Prevalence and correlates of elevated serum creatinine levels the Framingham Heart Study. Arch Intern Med 1999 159 1785-1790. [Pg.816]

Lauer MS, Okin PM, Larson MG, et al. Impaired heart rate response to graded exercise prognostic implications of chronotropic incompetence in the Framingham Heart Study. [Pg.79]

Lloyd-Jones DM, Wang TJ, Leip EP, et al. Lifetime risk for development of atrial fibrillation the Framingham Heart Study. Circulation 2004 110 1042-6. [Pg.116]

Benjamin EJ, Levy D, Vaziri SM, D Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA 1994 271 840-4. [Pg.116]

The National Institutes of Health (NIH) makes available to the public a web-based database of large population studies, beginning with the Framingham Heart Study, which has studied 9,000 participants over three generations and found 550,000 genetic variants by SNP analysis. [Pg.14]

This has been done within several major population studies. The most famous is the one initiated over 60 years ago in the United States. The Framingham Heart Study began in 1948, to try to delineate those factors that underlie heart attacks and strokes. The study established that high blood cholesterol concentration is a... [Pg.397]

Tai, E.S. et al.. Polyunsaturated fatty acids interact with the PPARA-L162V polymorphism to affect plasma triglyceride and apolipoprotein C-III concentrations in the Framingham Heart Study, J. Nutr., 135, 397, 2005. [Pg.10]

Bikkina, M., M.G. Larson, and D. Levy, Prognostic implications of asymptomatic ventricular arrhythmias the Framingham Heart Study. Ann Intern Med, 1992. 117(12) p. 990-6. [Pg.536]

The Framingham Heart Study. No better illustration exists of an epidemiologic study that has profoundly affected public health and generated a plethora of products in the process than the Framingham Heart Study, which is still operating. [Pg.714]

Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...